You already made the hard decisions. You chose to keep going after a diagnosis that made other clinics hesitant. You trusted a protocol — mini-IVF, natural cycle, gentle stimulation — that treated your body as an individual rather than a statistic. You got here.

And now, with a due date on the calendar and a delivery bag to pack, there is one more decision worth your attention — and unlike everything that came before it, this one is simple, free, and has a window that closes the moment your baby is born.

Cord blood banking after IVF is a topic that rarely comes up in the fertility clinic. By the time a patient reaches the delivery room, the conversation has moved on. But for patients who have navigated complex fertility journeys — diminished ovarian reserve, failed cycles elsewhere, recurrent pregnancy loss, fertility after 40 — the case for banking your newborn's stem cells is not just compelling. It is uniquely compelling, for reasons specific to the path you took to get here.

As a Hanabusa IVF graduate, you qualify for a complimentary AlphaCord newborn stem cell collection kit — a $850 value, at no cost — covering cord blood collection, processing, shipping, and your first full year of storage. We will explain what that means, why it matters, and why the patients who should think hardest about it are often exactly the ones least likely to hear about it.

What Newborn Stem Cells Are — and Why This Is a One-Time Opportunity

The umbilical cord and placenta that sustained your pregnancy contain something remarkable: a concentrated source of stem cells that exist, in this form, only at the moment of birth. Once your baby is delivered and the cord is clamped, that biological resource is gone. It cannot be retrieved. It cannot be replicated. The delivery room is the only place and time it ever exists.

💡 A single placenta can yield up to 10 times more stem cells than cord blood alone — yet it is routinely discarded at delivery unless parents have arranged collection in advance.

Three distinct stem cell populations are available at birth, each with its own biology and clinical significance:

• Cord blood is rich in haematopoietic stem cells (HSCs) — the cells responsible for producing every type of blood and immune cell in the body. For more than 30 years, cord blood HSCs have been used in clinical medicine to treat over 80 conditions, including leukaemia, lymphoma, sickle cell disease, thalassaemia, aplastic anaemia, and severe immunodeficiencies. This is not a future promise — it is an established treatment modality practised in hospitals worldwide.
• Cord tissue (the Wharton's jelly of the umbilical cord) contains mesenchymal stem cells (MSCs) — a different cell type with a different set of capabilities. MSCs are involved in tissue repair, immune modulation, and regenerative processes. They are currently the subject of more than 1,000 active clinical trials exploring applications in conditions from cerebral palsy to autoimmune disease to orthopaedic repair.
• Placental tissue is one of the most stem-cell-dense biological materials available at any point in life. Preserving it alongside cord blood and cord tissue maximises what is available to your child — and potentially to your wider family — across decades.

AlphaCord's 3-in-1 collection kit captures all three in a single coordinated procedure performed by your delivery team immediately after birth. It is non-invasive, takes minutes, and is compatible with delayed cord clamping when arranged in advance with your care provider.

What the Science Says About Stem Cell Banking After a Complex Pregnancy

The evidence base for cord blood banking is one of the most mature in regenerative medicine — built over three decades of peer-reviewed research, not marketing.

A comprehensive 2016 review in Biology of Blood and Marrow Transplantation confirmed cord blood transplantation as an effective treatment for more than 80 haematological and immunological conditions, and specifically highlighted the clinical advantage of autologous (self-donated) stem cells — cells from the patient's own body — in situations where a matched family or registry donor cannot be identified. The biological match of a child's own cord blood to themselves is absolute: zero risk of rejection, zero search time, zero uncertainty about availability.

On the regenerative frontier, MSCs from cord tissue are showing increasing promise. A 2020 phase II trial published in Stem Cells Translational Medicine demonstrated statistically significant improvements in gross motor function in children with cerebral palsy who received infusions of their own banked autologous cord blood — with stronger outcomes in the autologous group than in those who received cord blood from unrelated donors. The self-match is not a trivial detail: it is a clinically meaningful variable.

Beyond existing applications, over 4,000 active clinical trials are currently registered worldwide involving cord blood or cord tissue stem cells. The treatments being explored today — for type 1 diabetes, hearing loss, autism spectrum disorder, stroke, spinal cord injury — may become standard care within your child's lifetime. Cells banked now remain viable across decades of cryopreservation, meaning a collection made in the delivery room today could support treatments that do not yet exist in clinical practice.

There is also an emerging, early-stage body of research exploring whether banked MSCs may have future relevance not only for the child but for the mother — particularly in the context of regenerative and anti-inflammatory applications. This science is not yet at the stage of clinical recommendation, but it is a legitimate and growing area of investigation that is worth awareness, particularly for patients who have experienced pregnancy complications or whose bodies have been through prolonged fertility treatment.

Why the IVF Journey Itself Makes This Conversation More Important

Here is what rarely gets said directly: patients who conceive through IVF — particularly those who did so after years of complex treatment — have specific reasons to think carefully about cord blood banking that general-population resources simply do not address.

• Maternal age at delivery. Hanabusa IVF's patient population skews toward women in their 30s and 40s — women who were told elsewhere that their options were limited, and who found a path forward through personalised, lower-stimulation protocols. A child born to a mother over 40 has, statistically, a lower likelihood of having a younger sibling whose stem cells could serve as a potential family match. The child's own cord blood may be the only banked biological resource available to them within the family.
• Diminished ovarian reserve and complex histories. Patients with DOR, premature ovarian insufficiency, or recurrent pregnancy loss often carry a heightened awareness — earned through experience — that the body's biological resources are finite and not to be taken for granted. That same instinct applies here. The cord, the placenta, and everything they contain exist only once. Banking them is an extension of the same protective intention that drove the decision to seek specialist fertility care.
• International patients. A meaningful proportion of Hanabusa IVF's patients travel from outside the United States — from Japan, South Korea, Southeast Asia, the Middle East, and beyond. International patients who deliver in San Diego and then return home should be aware that AlphaCord's storage facility is US-based, FDA registered, and AABB accredited — representing a level of regulatory oversight that may not be available in their home country. For these families, banking in the US through AlphaCord can represent access to infrastructure and standards that are genuinely difficult to replicate elsewhere.
• Donor-egg patients. Hanabusa IVF's partnership with Asian Egg Bank means a significant number of graduates conceived using donor eggs. For these families — as with donor sperm or embryo donation — the child may not have identifiable genetic half-siblings available as potential stem cell donors. Their own cord blood and tissue cells are always their perfect match, regardless of the genetic origin of the egg.

How Hanabusa IVF Supports Its Graduates Beyond the Clinic

Hanabusa IVF's approach has always been about the individual — not the protocol, not the average outcome, not the standard path. That philosophy does not end at the embryo transfer or the positive pregnancy test. It extends into how we support our graduates as they move toward delivery and beyond.

Our partnership with AlphaCord — part of the same CSG.BIO Group that includes Hanabusa IVF — is one expression of that commitment. AlphaCord was founded in 2002 by parents who believed that cord blood banking should be accessible to every family, not just those who could afford premium private banking. Their laboratory is AABB accredited and FDA registered, operating under standards of quality and regulatory compliance that mirror Hanabusa IVF's own accreditations — CAP, QUAD A, and FDA registration.

As a Hanabusa IVF graduate, here is how to claim your complimentary kit:

1. Step 1 — Register: Ask your care team at Hanabusa IVF to provide you with the registration link, it takes under a minute.
2. Step 2 — Receive your promo code: A promo code arrives by email covering the full cost of your kit, processing, shipping, and first year of storage — $850 of value at no cost to you.
3. Step 3 — Kit ships to your home: Pack it in your hospital bag before your due date. Everything your delivery team needs is inside.
4. Step 4 — Collection at birth: Your obstetrician or midwife collects cord blood, cord tissue, and placental tissue immediately after delivery — a painless, minutes-long procedure that does not interrupt your birth plan.
5. Step 5 — AlphaCord takes it from there: Temperature-controlled courier collection, processing within 24 hours at their Indiana facility, and long-term cryopreservation in secure, monitored storage.

For international Hanabusa patients planning to deliver in the US and return home, please speak with your care coordinator about logistics — our international program team is experienced in supporting patients through delivery planning, post-birth coordination, and everything the transition home involves. You can learn more about our full range of fertility services here.

Frequently Asked Questions

I conceived through IVF with donor eggs. Are the cord blood cells still my baby's own?

Yes, completely. The stem cells collected from your baby's cord blood, cord tissue, and placenta are entirely your child's own biological material — carrying their own unique DNA. The genetic origin of the egg used in conception does not affect the stem cells present in the cord or placenta at birth. Your baby's banked cells will always be a perfect match for themselves.

Does collection interfere with delayed cord clamping?

No. AlphaCord's collection protocol is fully compatible with delayed cord clamping. You should inform your delivery care team and hospital in advance that you have a collection kit, so timing can be coordinated. Most US hospitals are familiar with cord blood collection kits and will accommodate your preferences without difficulty.

My fertility journey was long and difficult. Is there any reason cord blood banking matters more for me specifically?

For patients who conceived after complex treatment — DOR, failed cycles elsewhere, fertility after 40, recurrent pregnancy loss — several factors make banking particularly worth considering: the likelihood of a smaller family with fewer potential sibling donors, the possibility of donor genetics that make registry matching more complex, and the straightforward reality that the cord and placenta represent a biological resource that will never be available again. None of this is about fear — it is about informed decision-making, which is what every Hanabusa patient deserves.

How long can cryopreserved stem cells remain viable?

The science of cryopreservation at ultra-low temperatures essentially suspends cellular ageing. Peer-reviewed data supports viability across decades, and AlphaCord has maintained continuous storage since its founding in 2002. Cells banked today should remain viable well into your child's adult life, potentially for applications in treatments that do not yet exist in clinical practice.

Is AlphaCord a trustworthy, regulated facility?

Yes. AlphaCord is AABB and AATB accredited and FDA registered, with over two decades of continuous operation. AlphaCord is part of the CSG.BIO Group — the same group that includes Hanabusa IVF — and shares the group's commitment to quality, regulatory compliance, and patient-centred care.

You Fought Hard to Get Here. Let's Protect What You Built.

The patients who walk through Hanabusa IVF's doors are not ordinary patients. They are people who were told no — by other clinics, by statistics, sometimes by their own bodies — and who kept looking for a different answer. Dr. Lyndon Chang, Dr. Diana LeBlanc, and the Hanabusa team built this practice for exactly those patients, because they believe that complex cases deserve thoughtful, individualised care rather than a one-size-fits-all protocol.

That same belief extends to this moment. Your baby's cord blood and stem cells exist once, in the delivery room, for a matter of hours. Banking them is the last step in a journey you have already shown remarkable commitment to completing — and as a Hanabusa graduate, it costs you nothing.

For questions about your upcoming delivery, your post-treatment care, or anything else on your mind as you approach this next chapter — we are here.

→ Book a Consultation at Hanabusa IVF

‍